Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-02-16
1996-02-06
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514212, 514278, 514414, 514462, 514567, A61K 3140, A61K 3155, A61K 3144, A61K 31335, A61K 3134
Patent
active
054896070
ABSTRACT:
The instant invention is a method of using known compounds, such as (-)-5.alpha.,7.alpha.,-8.beta.-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4 .5]dec-8-yl]-4-benzofuranacetamide, as agents for treating benign prostatic hyperplasia.
REFERENCES:
patent: 4737493 (1988-04-01), Horwell
patent: 4965278 (1990-10-01), Horwell et al.
patent: 5063242 (1991-11-01), Horwell et al.
patent: 5317028 (1994-05-01), McKnight et al.
patent: 5369120 (1994-11-01), Woodruff
D. H. Peters, et al., Drugs, 1993, 46:1, 177-208.
J. Monda, et al., Mayo Clinic Proc, 1993, 68:670-679.
S. L. Robins, et al., Pathologic Basis of Disease, 1994, 5:1025-6.
Breider Michael A.
Courtney Cynthia L.
De La Iglesia Felix A.
Gough Alexander W.
Metz Alan L.
Anderson Elizabeth M.
Goldberg Jerome D.
Warner-Lambert & Company
LandOfFree
Use of enadoline in the treatment of benign prostatic enlargemen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of enadoline in the treatment of benign prostatic enlargemen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of enadoline in the treatment of benign prostatic enlargemen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2175383